Cargando…
Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart
BACKGROUND: Newborns with hypoplastic left heart (HLH) are usually palliated with the Norwood procedure or a hybrid stage I procedure. Hybrid is our preferred approach. Given the critical relationship between stage I, interstage, and comprehensive stage II or advanced biventricular repair, we hypoth...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997825/ https://www.ncbi.nlm.nih.gov/pubmed/33713024 http://dx.doi.org/10.1007/s40272-021-00438-2 |
_version_ | 1783670412853379072 |
---|---|
author | Mienert, Tino Esmaeili, Anoosh Steinbrenner, Blanka Khalil, Markus Müller, Matthias Akintuerk, Hakan Kerst, Gunter Schranz, Dietmar |
author_facet | Mienert, Tino Esmaeili, Anoosh Steinbrenner, Blanka Khalil, Markus Müller, Matthias Akintuerk, Hakan Kerst, Gunter Schranz, Dietmar |
author_sort | Mienert, Tino |
collection | PubMed |
description | BACKGROUND: Newborns with hypoplastic left heart (HLH) are usually palliated with the Norwood procedure or a hybrid stage I procedure. Hybrid is our preferred approach. Given the critical relationship between stage I, interstage, and comprehensive stage II or advanced biventricular repair, we hypothesized that appropriate drug treatment is a significant therapeutic cornerstone, especially for the management of the high-risk interstage. METHODS: We report a single-center observational study addressing the cardiovascular effects of, in particular, oral β-blockers and the additional use of angiotensin-converting enzyme (ACE) and mineralocorticoid inhibitors. RESULTS: In total, 51 newborns—30 with HLH syndrome (HLHS) and 21 with HLH complex (HLHC)—with a median bodyweight of 3.0 kg (range 1.9–4.4; nine with bodyweight ≤ 2500 g) underwent an uneventful “Giessen hybrid approach” using a newly approved duct stent. All patients were discharged home with a single, double or triple therapy consisting of ß-blockers, ACE and mineralocorticoid inhibitors; 90% of the patients received bisoprolol, 10% received propranolol, 72% received lisinopril, and 78% received spironolactone. Resting heart rate decreased from 138 bpm (range 112–172; n = 51) at admission to 123 bpm (range 99–139; n = 51) at discharge and 110 bpm before stage II/biventricular repair/heart transplantation (range 90–140; n = 37) accompanied by favorable bodyweight gain. No side effects were evident. CONCLUSION: In view of drug risk/benefit profiles, as well as the variable morphology and hemodynamics, the highly selective β1-adrenoceptor blocker bisoprolol is our preferred drug for treatment of HLHS/HLHC in the interstage. We avoid using ACE inhibitor monotherapy and exclude potential risks for coronary and cerebral perfusion pressure beforehand. |
format | Online Article Text |
id | pubmed-7997825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-79978252021-04-16 Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart Mienert, Tino Esmaeili, Anoosh Steinbrenner, Blanka Khalil, Markus Müller, Matthias Akintuerk, Hakan Kerst, Gunter Schranz, Dietmar Paediatr Drugs Original Research Article BACKGROUND: Newborns with hypoplastic left heart (HLH) are usually palliated with the Norwood procedure or a hybrid stage I procedure. Hybrid is our preferred approach. Given the critical relationship between stage I, interstage, and comprehensive stage II or advanced biventricular repair, we hypothesized that appropriate drug treatment is a significant therapeutic cornerstone, especially for the management of the high-risk interstage. METHODS: We report a single-center observational study addressing the cardiovascular effects of, in particular, oral β-blockers and the additional use of angiotensin-converting enzyme (ACE) and mineralocorticoid inhibitors. RESULTS: In total, 51 newborns—30 with HLH syndrome (HLHS) and 21 with HLH complex (HLHC)—with a median bodyweight of 3.0 kg (range 1.9–4.4; nine with bodyweight ≤ 2500 g) underwent an uneventful “Giessen hybrid approach” using a newly approved duct stent. All patients were discharged home with a single, double or triple therapy consisting of ß-blockers, ACE and mineralocorticoid inhibitors; 90% of the patients received bisoprolol, 10% received propranolol, 72% received lisinopril, and 78% received spironolactone. Resting heart rate decreased from 138 bpm (range 112–172; n = 51) at admission to 123 bpm (range 99–139; n = 51) at discharge and 110 bpm before stage II/biventricular repair/heart transplantation (range 90–140; n = 37) accompanied by favorable bodyweight gain. No side effects were evident. CONCLUSION: In view of drug risk/benefit profiles, as well as the variable morphology and hemodynamics, the highly selective β1-adrenoceptor blocker bisoprolol is our preferred drug for treatment of HLHS/HLHC in the interstage. We avoid using ACE inhibitor monotherapy and exclude potential risks for coronary and cerebral perfusion pressure beforehand. Springer International Publishing 2021-03-13 2021 /pmc/articles/PMC7997825/ /pubmed/33713024 http://dx.doi.org/10.1007/s40272-021-00438-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Article Mienert, Tino Esmaeili, Anoosh Steinbrenner, Blanka Khalil, Markus Müller, Matthias Akintuerk, Hakan Kerst, Gunter Schranz, Dietmar Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart |
title | Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart |
title_full | Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart |
title_fullStr | Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart |
title_full_unstemmed | Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart |
title_short | Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart |
title_sort | cardiovascular drug therapy during interstage after hybrid approach: a single-center experience in 51 newborns with hypoplastic left heart |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997825/ https://www.ncbi.nlm.nih.gov/pubmed/33713024 http://dx.doi.org/10.1007/s40272-021-00438-2 |
work_keys_str_mv | AT mienerttino cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT esmaeilianoosh cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT steinbrennerblanka cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT khalilmarkus cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT mullermatthias cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT akintuerkhakan cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT kerstgunter cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart AT schranzdietmar cardiovasculardrugtherapyduringinterstageafterhybridapproachasinglecenterexperiencein51newbornswithhypoplasticleftheart |